生命科学资讯

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Roche announces positive phase II results for experimental obesity drug - wkzo.com

Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com

Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital

Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital

Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com

Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News

Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech

Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace

AI-based Digital Pathology Market Intelligence Report, 2025-2035, Featuring Aiforia Technologies, Ibex Medical Analytics, Indica Labs, PathAI, Roche, Visiopharm and Many Other Key Players - ResearchAndMarkets.com - The AI Journal

Emerson and Roche Collaborate on Digital Modality Library for Pharmaceutical Development - Automation World

Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma - Medical Dialogues

ROG.SW News Today: Trump Drug Plan Boosts Roche Stock on December 22 - Meyka

Roche and Novartis close to price agreement with Trump - medwatch.com

Roche hails giredestrant effect in ER-positive early-stage breast cancer - The Pharma Letter

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech

Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche's Flatiron - Fierce Biotech